Precursor Cell Lymphoblastic Leukemia-lymphoma Clinical Trial
Official title:
Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory Acute Lymphoblastic Leukemia, With or Without Extramedullary Disease, or Relapsed or Refractory Lymphoblastic Lymphoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), safety and toxicity, and pharmacokinetics (PK) of ixazomib administered intravenously in combination with multiagent reinduction chemotherapy in pediatric participants with relapsed/refractory ALL or LLy.
29-Apr-2020 Enrollment of new patients into this study has been paused due to the COVID-19
situation. The duration of this pause is dependent on the leveling and control of the
COVID-19 pandemic.
The drug being tested in this study is called Ixazomib. Ixazomib is being tested to determine
the MTD or RP2D of intravenous ixazomib when administered in combination with multiagent
chemotherapy (reinduction therapy) in pediatric participants with relapsed or refractory ALL
or relapsed/refractory LLy.
The study will enroll approximately 18 participants. Doses of ixazomib will be escalated
according to a standard 3+3 dose escalation schema. Participants aged >= 1 year will receive
the starting dose of 1.0 mg/m^2 and participants aged <1 year will receive the starting dose
of 0.03 mg/kg. Ixazomib will be administered in combination with multiagent reinduction
therapy. The dose escalation phase will determine the MTD and/or RP2D of ixazomib. Dose
escalation will be based on the observed safety and tolerability data.
Participants aged <1 year will be assessed separately and will not contribute to the dose
escalation assessment.
This multi-center trial will be conducted in the United States and Spain. The overall time to
participate in this study is approximately 30 months. Participants will be followed up to Day
60 after the first dose of study drug for a follow-up assessment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05024357 -
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
|
N/A | |
| Recruiting |
NCT05026229 -
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
|
N/A | |
| Completed |
NCT03545659 -
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
|
||
| Completed |
NCT03985826 -
Health Care Utilisation Among Survivors of Childhood Acute Lymphoblastic Leukaemia
|
||
| Recruiting |
NCT05660473 -
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Completed |
NCT03743246 -
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05968963 -
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
|
N/A | |
| Active, not recruiting |
NCT01429610 -
Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Completed |
NCT03384654 -
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
|
Phase 2 | |
| Completed |
NCT01317940 -
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02454270 -
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
|
Phase 1 | |
| Completed |
NCT01331590 -
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
|
Phase 0 | |
| Completed |
NCT04456959 -
InO - A Retrospective Study of UK Patients With Leukaemia
|
||
| Recruiting |
NCT03462095 -
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
|
N/A | |
| Completed |
NCT01386619 -
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03985215 -
The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family Perspectives
|
||
| Recruiting |
NCT02328950 -
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
|
N/A | |
| Withdrawn |
NCT02973191 -
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05873322 -
Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
|
||
| Recruiting |
NCT02390752 -
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
|
Phase 1 |